Cargando…

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients

Chronic Myeloid Leukemia (CML) is a stem cell disease sustained by a rare population of quiescent cells which are to some extent resistant to tyrosine kinase inhibitors (TKIs). BCR-ABL oncogene activates multiple cross-talking signal transduction pathways (STP), such as RAS/MEK/ERK, PI3K/Akt, Wnt an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ricciardi, Maria Rosaria, Salvestrini, Valentina, Licchetta, Roberto, Mirabilii, Simone, Forcato, Mattia, Gugliotta, Gabriele, Salati, Simona, Castagnetti, Fausto, Rosti, Gianantonio, Breccia, Massimo, Alimena, Giuliana, Manfredini, Rossella, Bicciato, Silvio, Lemoli, Roberto Massimo, Tafuri, Agostino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955129/ https://www.ncbi.nlm.nih.gov/pubmed/29774100 http://dx.doi.org/10.18632/oncotarget.24938

Ejemplares similares

Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells
por: Salati, Simona, et al.
Publicado: (2017)

The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia
por: Allegretti, Matteo, et al.
Publicado: (2015)

Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia
por: Allegretti, Matteo, et al.
Publicado: (2016)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Treatment Recommendations for Chronic Myeloid Leukemia
por: Baccarani, Michele, et al.
Publicado: (2014)

Current treatment approaches in CML
por: Castagnetti, Fausto, et al.
Publicado: (2019)

mTOR Regulation of Metabolism in Hematologic Malignancies
por: Mirabilii, Simone, et al.
Publicado: (2020)

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia
por: Mancini, Manuela, et al.
Publicado: (2017)

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
por: Luciano, Luigia, et al.
Publicado: (2023)

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Tramesan, a novel polysaccharide from Trametes versicolor. Structural characterization and biological effects
por: Scarpari, Marzia, et al.
Publicado: (2017)

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia
por: Iacovelli, Stefano, et al.
Publicado: (2015)

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
por: Breccia, Massimo, et al.
Publicado: (2008)

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
por: Breccia, Massimo, et al.
Publicado: (2014)

Biological Aspects of mTOR in Leukemia
por: Mirabilii, Simone, et al.
Publicado: (2018)

Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics
por: Carpiuc, Kimbach Tran, et al.
Publicado: (2010)

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
por: Mancini, Manuela, et al.
Publicado: (2022)

A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review
por: Piedimonte, Monica, et al.
Publicado: (2019)

IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia
por: Fiordi, Benedetta, et al.
Publicado: (2023)

Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite
por: Ricciardi, M. R., et al.
Publicado: (2017)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
por: Martinelli, Giovanni, et al.
Publicado: (2007)

Systematic review of dasatinib in chronic myeloid leukemia
por: Breccia, Massimo, et al.
Publicado: (2013)

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
por: Breccia, Massimo, et al.
Publicado: (2017)

Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study
por: Iurlo, Alessandra, et al.
Publicado: (2022)

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy
por: Luatti, Simona, et al.
Publicado: (2017)

Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
por: Bocchia, Monica, et al.
Publicado: (2018)

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib
por: Breccia, Massimo, et al.
Publicado: (2016)

Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia
por: Latagliata, Roberto, et al.
Publicado: (2016)

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
por: Soverini, Simona, et al.
Publicado: (2016)

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
por: Gugliotta, Gabriele, et al.
Publicado: (2017)

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
por: Annunziata, Mario, et al.
Publicado: (2020)

Doxorubicin-Induced Cardiac Senescence Is Alleviated Following Treatment with Combined Polyphenols and Micronutrients through Enhancement in Mitophagy
por: Foglio, Eleonora, et al.
Publicado: (2023)

Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase.
por: Breccia, Massimo, et al.
Publicado: (2011)

Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective
por: Rontauroli, Sebastiano, et al.
Publicado: (2022)

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
por: Soverini, Simona, et al.
Publicado: (2016)

Metabolic Reprogramming Promotes Myogenesis During Aging
por: Belli, Roberta, et al.
Publicado: (2019)

Corrigendum: Metabolic Reprogramming Promotes Myogenesis During Aging
por: Belli, Roberta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cr00rmbg3sradi8osh40h5dee5